---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-004649"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:23:08.754226+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech reports Q3 net loss $1.7M; ARDS drug selected for U.S. government study

## Summary
- Net loss of $1.7M ($0.52/shr) vs $2.0M ($0.68/shr) a year ago; nine-month loss $5.2M ($1.64/shr).
- Cash $2.0M; working capital $0.7M; received $300K post-quarter from Canadian govt SIF fund.
- EB05 (paridiprubart) chosen for HHS-funded ARDS platform study; Edesa supplies drug and tech support.
- Preparing IND for Phase 2 vitiligo study of anti-CXCL10 technology in moderate-to-severe patients.
- Q3 operating expenses $1.9M, down $0.2M YoY; R&D $0.9M, down $0.1M.

## SEC filing metadata
- accession: 0001171843-24-004649
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000117184324004649/0001171843-24-004649-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000117184324004649/f8k_080924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-004649
- JSON: https://secwatch.observer/filing/0001171843-24-004649.json
- Plain text: https://secwatch.observer/filing/0001171843-24-004649.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.